Norinchukin Bank The raised its holdings in CIGNA Co. (NYSE:CI) by 5.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,712 shares of the health services provider’s stock after purchasing an additional 972 shares during the period. Norinchukin Bank The’s holdings in CIGNA were worth $4,003,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. Saratoga Research & Investment Management purchased a new position in shares of CIGNA in the third quarter worth about $112,000. Iguana Healthcare Management LLC increased its stake in shares of CIGNA by 51.4% in the third quarter. Iguana Healthcare Management LLC now owns 26,500 shares of the health services provider’s stock worth $4,954,000 after purchasing an additional 9,000 shares in the last quarter. Ascension Asset Management LLC purchased a new position in shares of CIGNA in the fourth quarter worth about $473,000. Schwab Charles Investment Management Inc. increased its stake in shares of CIGNA by 3.4% in the fourth quarter. Schwab Charles Investment Management Inc. now owns 904,143 shares of the health services provider’s stock worth $183,623,000 after purchasing an additional 29,553 shares in the last quarter. Finally, Sectoral Asset Management Inc increased its stake in shares of CIGNA by 194.1% in the third quarter. Sectoral Asset Management Inc now owns 45,615 shares of the health services provider’s stock worth $8,527,000 after purchasing an additional 30,105 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.
Several equities analysts have recently weighed in on CI shares. Zacks Investment Research upgraded shares of CIGNA from a “hold” rating to a “buy” rating and set a $231.00 target price for the company in a research note on Friday, December 22nd. Royal Bank of Canada restated an “outperform” rating and issued a $220.00 price objective (up from $185.00) on shares of CIGNA in a research report on Friday, November 3rd. Jefferies Group raised their price objective on shares of CIGNA from $221.00 to $231.00 and gave the company a “buy” rating in a research report on Friday, November 3rd. Goldman Sachs Group began coverage on shares of CIGNA in a research report on Wednesday, January 3rd. They issued a “neutral” rating and a $247.00 price objective for the company. Finally, Credit Suisse Group began coverage on shares of CIGNA in a research report on Thursday, November 2nd. They issued an “outperform” rating and a $219.00 price objective for the company. Three equities research analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. CIGNA currently has an average rating of “Buy” and a consensus price target of $210.12.
Shares of CIGNA Co. (NYSE CI) opened at $193.81 on Tuesday. The firm has a market cap of $47,283.25, a P/E ratio of 18.55, a PEG ratio of 1.16 and a beta of 0.45. The company has a quick ratio of 0.39, a current ratio of 0.37 and a debt-to-equity ratio of 0.38. CIGNA Co. has a 1-year low of $141.93 and a 1-year high of $227.13.
CIGNA (NYSE:CI) last announced its quarterly earnings data on Thursday, February 1st. The health services provider reported $1.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.87 by $0.07. The firm had revenue of $10.53 billion during the quarter, compared to analyst estimates of $10.28 billion. CIGNA had a net margin of 5.38% and a return on equity of 18.84%. The business’s quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the previous year, the business posted $1.87 EPS. research analysts predict that CIGNA Co. will post 12.9 earnings per share for the current year.
In other news, Chairman Isaiah Harris, Jr. sold 212 shares of the business’s stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $209.35, for a total value of $44,382.20. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP John M. Murabito sold 28,037 shares of the business’s stock in a transaction that occurred on Wednesday, January 10th. The stock was sold at an average price of $205.68, for a total transaction of $5,766,650.16. Following the completion of the sale, the executive vice president now owns 60,290 shares of the company’s stock, valued at $12,400,447.20. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 64,663 shares of company stock valued at $13,329,903. Company insiders own 1.30% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This piece of content was originally reported by The Ledger Gazette and is the property of of The Ledger Gazette. If you are reading this piece of content on another domain, it was stolen and republished in violation of international trademark and copyright laws. The original version of this piece of content can be accessed at https://ledgergazette.com/2018/02/20/cigna-co-ci-shares-bought-by-norinchukin-bank-the.html.
CIGNA Company Profile
Cigna Corporation (Cigna), together with its subsidiaries, is a health services company. The Company offers medical, dental, disability, life and accident insurance and related products and services. The Company’s segments include Global Health Care, Global Supplemental Benefits, Group Disability and Life, and Other Operations and Corporate.
Receive News & Ratings for CIGNA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CIGNA and related companies with MarketBeat.com's FREE daily email newsletter.